Bridge Biotherapeutics, Inc. (KOSDAQ:288330)

Bridge Biotherapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	5,737	14,183	7,942	8,200	20,943
Short-Term Investments	9,940	6,000	39,500	29,000	37,000
Trading Asset Securities	6,086	-	3,852	5,928	-
Cash & Short-Term Investments	21,763	20,183	51,295	43,128	57,943
Cash Growth	7.83%	-60.65%	18.94%	-25.57%	-16.21%
Accounts Receivable	1.15	-	-	-	572.25
Other Receivables	332.53	647.21	904.91	365.75	1,171
Receivables	633.68	647.21	904.91	365.75	1,743
Prepaid Expenses	159.03	217.98	274.3	305.32	313.24
Other Current Assets	804.53	683.24	2,483	627.33	304.74
Total Current Assets	23,360	21,731	54,957	44,426	60,304
Property, Plant & Equipment	3,037	4,287	3,784	664.25	829.58
Long-Term Investments	953.54	890.53	470.01	94.06	0
Goodwill	2,367	2,888	-	-	-
Other Intangible Assets	2,875	2,777	131.89	179.22	223.78
Long-Term Deferred Charges	85.24	85.24	-	-	-
Other Long-Term Assets	813.8	1,564	2,112	1,293	2,153
Total Assets	33,492	34,222	61,455	46,657	63,510
Accrued Expenses	165.05	330.51	142.66	119.58	105.07
Current Portion of Leases	1,192	1,043	993.06	172.93	168.14
Current Unearned Revenue	-	-	-	1,076	-
Other Current Liabilities	2,518	9,002	6,359	2,188	782.26
Total Current Liabilities	3,875	10,375	7,494	3,556	1,055
Long-Term Leases	1,434	2,504	2,016	53.63	226.56
Long-Term Unearned Revenue	-	-	-	-	3,000
Long-Term Deferred Tax Liabilities	532.97	532.97	-	-	-
Other Long-Term Liabilities	86.38	83.22	80.17	0	-0
Total Liabilities	5,928	13,496	9,590	3,610	4,282
Common Stock	25,206	11,334	9,948	9,854	9,591
Additional Paid-In Capital	136,432	122,612	115,998	71,820	65,537
Retained Earnings	-149,473	-129,718	-87,397	-45,697	-19,419
Treasury Stock	-10.34	-	-	-	-
Comprehensive Income & Other	13,532	13,269	10,945	7,071	3,519
Total Common Equity	25,686	17,497	49,494	43,047	59,228
Minority Interest	1,319	1,349	-	-	-
Shareholders' Equity	27,565	20,726	51,865	43,047	59,228
Total Liabilities & Equity	33,492	34,222	61,455	46,657	63,510
Total Debt	2,625	3,547	3,009	226.56	394.69
Net Cash (Debt)	19,138	16,636	48,286	42,901	57,548
Net Cash Growth	15.04%	-65.55%	12.55%	-25.45%	-16.59%
Net Cash Per Share	469.83	554.64	2028.30	1830.30	2517.32
Filing Date Shares Outstanding	49.84	27.2	23.88	23.65	23.02
Total Common Shares Outstanding	49.84	27.2	23.88	23.65	23.02
Working Capital	19,486	11,356	47,462	40,870	59,249
Book Value Per Share	515.42	643.25	2073.00	1820.27	2573.19
Tangible Book Value	20,444	11,832	49,363	42,868	59,004
Tangible Book Value Per Share	410.23	434.99	2067.48	1812.69	2563.46
Machinery	1,113	1,173	929.29	724.31	558.1
Construction In Progress	-	-	234.4	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.